medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2025-26-41-48medalphabet-4659Research ArticleСтатьиОтдаленные эффекты противоопухолевого лечения острого лимфобластного лейкозаLong-term effects of antitumor treatment of acute lymphoblastic leukemiahttps://orcid.org/0009-0004-1587-2087СиттигуллинаА. Р.SittigullinaA. R.

Ситтигуллина Адиля Рафиловна, врач-ординатор НИИ детской онкологии и гематологии им. акад. РАМН Л. А. Дурнова

Москва

Sittigullina Adilya R. resident at the Research Institute of Pediatric Oncology and Hematology named after academician of the Russian Academy of Medical Sciences L. A. Durnov

Moscow

rsittigullin@mail.ruhttps://orcid.org/0000-0001-7574-335XХарбедияВ. Х.KharbediyaV. Kh.

Харбедия Вахтанг Хвичевич, врач-детский онколог, зав. детским онкологическим реабилитационным отделением

Подольск

Kharbediya Vahtang Kh. pediatric oncologist, head of Pediatric Oncology Rehabilitation Dept

Podolsk

kharbediya1992@mail.ruhttps://orcid.org/0000-0001-5911-553XБелышеваТ. С.BelyshevaT. S.

Белышева Татьяна Сергеевна, д. м. н., ведущий научный сотрудник поликлинического отделения НИИ детской онкологии и гематологии им. акад. РАМН Л. А. Дурнова ФГБУ

Москва

Belysheva Tatiana S., DM Sci (habil.), leading researcher at Outpatient Dept of the Research Institute of Pediatric Oncology and Hematology named after academician of the Russian Academy of Medical Sciences L. A. Durnov

Moscow

klinderma@bk.ruФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава РоссииРоссияN. N. Blokhin National Medical Research Center of OncologyRussian FederationФедеральный детский реабилитационный центр «Кораблик» – структурное подразделение Российской детской клинической больницы – филиала ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России (Пироговский университет)РоссияFederal Children’s Rehabilitation Center «Korablik» – structural division of the Russian Children’s Clinical Hospital – branch of the N. I. Pirogov Russian National Research Medical UniversityRussian Federation202509112025026Диагностика и онкотерапия (3)41‑48Copyright © Ситтигуллина А.Р., Харбедия В.Х., Белышева Т.С., 20252025Ситтигуллина А.Р., Харбедия В.Х., Белышева Т.С.Sittigullina A.R., Kharbediya V.K., Belysheva T.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4659

Введение. В последние десятилетия удалось существенно повысить пятилетнюю выживаемость детей, перенесших острый лимфобластный лейкоз (ОЛЛ), которая в России превышает 90 %. Вместе с тем у данной группы пациентов сохраняются серьезные риски развития отдаленных эффектов терапии, включая вторичные злокачественные новообразования, кардиотоксичность, нейрокогнитивные нарушения, а также патологии опорно-двигательного аппарата и эндокринной системы. Основными факторами риска поздних эффектов являются: интенсивность и комбинация химио /лучевой терапии, возраст на момент лечения, генетическая предрасположенность (полиморфизмы генов, вариации генов ДНК-репарации), а также наличие сопутствующих заболеваний (врожденные патологии сердца, ожирение).Цель. Систематизация и обобщение современных данных о спектре и частоте поздних неблагоприятных эффектов у взрослых, излеченных от ОЛЛ в детском возрасте.Материалы и методы. Проведен структурированный обзор и анализ литературных данных в электронных медицинских базах данных PubMed, eLibrary за период с 1990 по 2024 г.Заключение. Данные обзора подчеркивают высокую распространенность разнообразных поздних неблагоприятных эффектов у детей, излеченных от ОЛЛ, и необходимость их систематического мониторинга.

Introduction. In recent decades, the five-year survival rate of children with acute lymphoblastic leukemia (ALL) in Russia has risen to over 90 %. At the same time, this group of patients remains at serious risk of developing long-term effects of therapy, including secondary malignant neoplasms, cardiotoxicity, neurocognitive disorders, as well as pathologies of the musculoskeletal apparatus and endocrine system. The main risk factors for late effects are: intensity and combination of chemotherapy/radiation therapy, age at the time of treatment, genetic predisposition (gene polymorphisms, variations in DNA repair genes), as well as the presence of concomitant diseases (congenital heart disease, obesity).Objective. To systematize and summarize current data on the spectrum and frequency of late adverse effects in patients treated for ALL during childhood.Materials and methods. Data were structured review and analyzed in electronic medical databases such as PubMed, eLibrary from 1990 to 2024.Conclusions. These reviews emphasize the high prevalence of a variety of late adverse effects in children cured of ALL and the need for their systematic monitoring.

острый лимфобластный лейкозпоздние отдаленные эффектыкардиотоксичностьвторые опухолинейрокогнитивные нарушенияacute lymphoblastic leukemialong-term effectscardiotoxicitysecond tumorsneurocognitive impairmentReferencesАлескерова Г. А., Шервашидзе М. А., Попа А. В., Валиев Т. Т., Курдюков Б. В., Батманова Н. А., Менткевич Г. Л. Результаты лечения острого лимфобластного лейкоза у детей по протоколу ALL IC-BFM 2002. Онкопедиатрия. 2016; 3 (4): 302–308.Aleskerova G. A., Shervashidze M. A., Popa A. V., Valiev T. T., Kurdjukov B. V., Batmanova N. A., Mentkevich G. L. Treatment Results of All IC-BFM 2002 Protocol in Children with Acute Lymphoblastic Leukemia. Onkopediatria. 2016; 3 (4): 302–308. (In Russ.). DOI: 10.15690/onco.v3i4.1635Saleh T. A., Al-Rubaye A.S., Noori A. S., Ibrahim I. K. Assessment of anthracycline-induced longterm cardiotoxicity in patients with hematological malignancies. Iraqi Journal of Hematology. 2019; 8 (2): 63–68. DOI: 10.4103/ijh.ijh_4_19Saleh T. A., Al-Rubaye A.S., Noori A. S., Ibrahim I. K. Assessment of anthracycline-induced longterm cardiotoxicity in patients with hematological malignancies. Iraqi Journal of Hematology. 2019; 8 (2): 63–68. DOI: 10.4103/ijh.ijh_4_19Виноградова Ю. Е., Луценко И. Н., Капланская И. Б., Воробьев И. А., Самойлова Р. С., Горгидзе Л. А., Рыжикова Н. А., Валиев Т. Т., Гилязитдинова Е. А., Джулакян У. Л., Егорова Е. К., Звонков Е. Е., Красильникова Б. Б., Магомедова А. У., Марголин О. В., Марьин Д. С., Кременецкая А. М., Кравченко С. К., Воробьев А. И. Эффективность терапии различных вариантов анаплазированных Т-крупноклеточных лимфом. Терапевтический архив. 2008; 80 (7): 33–37.Vinogradova Yu.E., Lutsenko I. N., Kaplanskaia I. B., Vorob’ev I.A., Samoĭlova R. S., Gorgidze L. A., Ryzhikova N. A., Valiev T. T., Giliazitdinova E. A., Dzhulakian U. L., Egorova E. K., Zvonkov E. E., Krasil’nikova B.B., Magomedova A. U., Margolin O. V., Mar’in D.S., Kremenetskaia A. M., Kravchenko S. K., Vorob’ev A. I. Efficacy of therapy of different variants of anaplastic large t-cell lymphomas. Terapevticheskii arkhiv. 2008; 80 (7): 33–37. (In Russ.).Валиев Т. Т., Морозова О. В., Ковригина А. М., Махонова Л. А., Шолохова Е. Н., Серебрякова И. Н., Попа А. В., Тупицын Н. Н., Менткевич Г. Л. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология. 2012; 57 (1): 3–9.Valiev T. T., Morozova O. V., Kovrigina A. M., Makhonova L. A., Sholokhova E. N., Serebryakova I. N., Popa A. V., Tupitsyn N. N., Mentkevich G. L. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Russian journal of hematology and transfusiology. 2012; 57 (1): 3–9. (In Russ.).van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010; 170 (14): 1247–1255. DOI: 10.1001/archinternmed.2010.233van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010; 170 (14): 1247–1255. DOI: 10.1001/archinternmed.2010.233Заева Г. Е., Валиев Т. Т., Гавриленко Т. Ф., Моисеенко Е. И., Медведовская Е. Г., Михайлова С. Н. и др. Отдаленные последствия терапии злокачественных опухолей у детей: 35-летний опыт клинических наблюдений. Современная онкология. 2016; 18 (1): 55–60.Zaeva G. E., Valiev T. T., Gavrilenko T. F. et al. Long-term effects of pediatric cancer therapy: 35-year clinical experience. Journal of Modern Oncology. 2015; 18 (1): 55–60. (In Russ.).Lipshultz SE, Lipsitz SR, Sallan SE. et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23 (12): 2629–2636. DOI: 10.1200/JCO.2005.11.015Lipshultz SE, Lipsitz SR, Sallan SE. et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23 (12): 2629–2636. DOI: 10.1200/JCO.2005.11.015Гурьева О. Д., Савельева М. И., Валиев Т. Т. Генетические основы клинических вариантов токсичности химиотерапии у детей с острым лимфобластным лейкозом (обзор литературы). Российский журнал детской гематологии и онкологии. 2021; 8(4): 60–70.Gurieva O. D., Savelyeva M. I., Valiev T. T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Russian Journal of Pediatric Hematology and Oncology. 2021;8(4):60–70. (In Russ.). DOI: 10.21682/2311‑1267‑2021‑8‑4‑60‑70Валиев Т. Т., Шервашидзе М. А., Белышева Т. С. Оценка токсичности терапии острого лимфобластного лейкоза по протоколу ALL IC-BFM 2002. Онкогематология. 2022; 17 (3) 137‑159.Valiev T. T., Shervashidze M. A., Belysheva T. S. Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002. Oncohematology. 2022;17(3):137–159. (In Russ.). DOI: 10.17650/1818‑8346‑2022‑17‑3‑137‑159Tjeerdsma G., Meinardi M. T., van der Graaf W. T. et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999; 81 (4): 419–423. DOI: 10.1136/hrt.81.4.419Tjeerdsma G., Meinardi M. T., van der Graaf W. T. et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999; 81 (4): 419–423. DOI: 10.1136/hrt.81.4.419Lipshultz S. E., Giantris A. L., Lipsitz S. R. et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. Journal of Clinical Oncology. 2002; 20 (6): 1677–1682. PMID: 11925514.Lipshultz S. E., Giantris A. L., Lipsitz S. R. et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. Journal of Clinical Oncology. 2002; 20 (6): 1677–1682. PMID: 11925514.Levitt G. A., Dorup I., Sørensen K., Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? British Journal of Haematology. 2004;124 (4): 463–468. DOI: 10.1111/j.1365-2141.2003.04992.xLevitt G. A., Dorup I., Sørensen K., Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? British Journal of Haematology. 2004;124 (4): 463–468. DOI: 10.1111/j.1365-2141.2003.04992.xTjeerdsma G., Meinardi M. T., van der Graaf W. T. et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999;81 (4): 419–423. DOI: 10.1136/hrt.81.4.419Tjeerdsma G., Meinardi M. T., van der Graaf W. T. et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999;81 (4): 419–423. DOI: 10.1136/hrt.81.4.419Shah C. P., Moreb J. S. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Therapeutic Advances in Cardiovascular Disease. 2019; 13: 175394471984343. DOI: 10.1177/1753944719843435Shah C. P., Moreb J. S. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Therapeutic Advances in Cardiovascular Disease. 2019; 13: 175394471984343. DOI: 10.1177/1753944719843435Pui CH, Cheng C, Leung W. et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003; 349: 640–649. DOI: 10.1056/NEJMoa035091Pui CH, Cheng C, Leung W. et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003; 349: 640–649. DOI: 10.1056/NEJMoa035091Neglia JP, Meadows AT, Robison LL. et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 325: 1330–1336. DOI: 10.1056/NEJM199111073251902Neglia JP, Meadows AT, Robison LL. et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 325: 1330–1336. DOI: 10.1056/NEJM199111073251902Sklar CA, Mertens AC, Mitby P. et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002; 87: 3136–3141. DOI: 10.1210/jcem.87.7.8606Sklar CA, Mertens AC, Mitby P. et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002; 87: 3136–3141. DOI: 10.1210/jcem.87.7.8606Marie-Cécile Le Deley et al. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie Pédiatrique. JCO 21: 1074–1081 (2003). DOI: 10.1200/JCO.2003.04.100Marie-Cécile Le Deley et al. Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie Pédiatrique. JCO 21: 1074–1081 (2003). DOI: 10.1200/JCO.2003.04.100Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R. Nordic Society for Paediatric Haematology and Oncology. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL‑92 study. Blood. 2009 Jun 11; 113 (24): 6077–84. DOI: 10.1182/blood‑2008‑11‑187880Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R. Nordic Society for Paediatric Haematology and Oncology. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL‑92 study. Blood. 2009 Jun 11; 113 (24): 6077–84. DOI: 10.1182/blood‑2008‑11‑187880Махачева Ф. А., Валиев Т. Т. Особенности вторичного острого миелоидного лейкоза у детей. Онкогематология. 2020; 15 (4): 12–17.Makhacheva F. A., Valiev T. T. Clinical features of secondary acute myeloid leukemia in children. Oncohematology. 2020; 15 (4): 12–17. (In Russ.). https://doi.org/10.17650/1818‑8346‑2020‑15‑4‑12‑17Валиев Т. Т., Павлова Т. Ю., Ковригина А. М., Серебрякова И. Н. Острый миелоидный лейкоз как вторая опухоль у больного лимфомой Беркитта: обзор литературы и клиническое наблюдение. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2021; 14 (2): 167–72.Valiev T. T., Pavlova T. Yu., Kovrigina A. M., Serebryakova I. N. Acute myeloid leukemia as second tumor in a patient with Burkitt’s lymphoma: literature review and a case report. Clinical Oncohematology. Basic Research and Clinical Practice. 2021; 14 (2): 167–72. (In Russ.). DOI: 10.21320/2500‑2139‑2021‑14‑2‑167‑172Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006 Sep; 91 (9): 3494–8. DOI: 10.1210/jc.2006-0656Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006 Sep; 91 (9): 3494–8. DOI: 10.1210/jc.2006-0656Fujii M, Ichikawa M, Iwatate K, Bakhit M, Yamada M, Kuromi Y, Sato T, Sakuma J, Sato H, Kikuta A, Suzuki Y, Saito K. Secondary brain tumors after cranial radiation therapy: A single-institution study. Rep Pract Oncol Radiother. 2020 Mar-Apr; 25 (2): 245–249. DOI: 10.1016/j.rpor.2020.01.009.Fujii M, Ichikawa M, Iwatate K, Bakhit M, Yamada M, Kuromi Y, Sato T, Sakuma J, Sato H, Kikuta A, Suzuki Y, Saito K. Secondary brain tumors after cranial radiation therapy: A single-institution study. Rep Pract Oncol Radiother. 2020 Mar-Apr; 25 (2): 245–249. DOI: 10.1016/j.rpor.2020.01.009.Коркина Ю. С., Валиев Т. Т. L-аспарагиназа: новое об известном препарате. Педиатрическая фармакология. 2021; 18 (3): 227–232.Korkina Yu.S., Valiev T. T. L-asparaginase: New about Well-Known Drug. Pediatric pharmacology. 2021; 18 (3): 227–232. (In Russ.). https://doi.org/10.15690/pf.v18i3.2282Journy NMY, Zrafi WS, Bolle S, Fresneau B, Alapetite C, Allodji RS, Berchery D, Haddy N, Kobayashi I, Labbé M, Pacquement H, Pluchart C, Schwartz B, Souchard V, Thomas-Teinturier C, Veres C, Vu-Bezin G, Diallo I, de Vathaire F. Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2021 Jan; 30 (1): 133–141. DOI: 10.1158/1055-9965Journy NMY, Zrafi WS, Bolle S, Fresneau B, Alapetite C, Allodji RS, Berchery D, Haddy N, Kobayashi I, Labbé M, Pacquement H, Pluchart C, Schwartz B, Souchard V, Thomas-Teinturier C, Veres C, Vu-Bezin G, Diallo I, de Vathaire F. Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2021 Jan; 30 (1): 133–141. DOI: 10.1158/1055-9965Lee CY, Chen YW, Lee YY, Chang FC, Chen HH, Lin SC, Ho DM, Huang MC, Yen SH, Wong TT, Liang ML. Irradiation-Induced Secondary Tumors following Pediatric Central Nervous System Tumors: Experiences of a Single Institute in Taiwan (1975–2013). Int J Radiat Oncol Biol Phys. 2018 Aug 1; 101 (5): 1243–1252. DOI: 10.1016/j.ijrobp.2018.04.032Lee CY, Chen YW, Lee YY, Chang FC, Chen HH, Lin SC, Ho DM, Huang MC, Yen SH, Wong TT, Liang ML. Irradiation-Induced Secondary Tumors following Pediatric Central Nervous System Tumors: Experiences of a Single Institute in Taiwan (1975–2013). Int J Radiat Oncol Biol Phys. 2018 Aug 1; 101 (5): 1243–1252. DOI: 10.1016/j.ijrobp.2018.04.032Le Deley M. C., Leblanc T., Shamsaldin A., Raquin M. A., Lacour B., Sommelet D., Chompret A., Cayuela J. M., Bayle C., Bernheim A., De Vathaire F., Vassal G., Hill C. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Société Française d’Oncologie Pédiatrique. Journal of Clinical Oncology. 2003; 21 (6): 1074–1081. https://doi.org/10.1200/JCO.2003.04.100Le Deley M. C., Leblanc T., Shamsaldin A., Raquin M. A., Lacour B., Sommelet D., Chompret A., Cayuela J. M., Bayle C., Bernheim A., De Vathaire F., Vassal G., Hill C. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Société Française d’Oncologie Pédiatrique. Journal of Clinical Oncology. 2003; 21 (6): 1074–1081. https://doi.org/10.1200/JCO.2003.04.100Mariël L. te Winkel, Rob Pieters, Wim C. J. Hop, Hester A. de Groot-Kruseman, Maarten H. Lequin, Inge M. van der Sluis, Jos P. M. Bökkerink, Jan A. Leeuw, Marrie C. A. Bruin, R. Maarten Egeler, Anjo J. P. Veerman, Marry M. van den Heuvel-Eibrink; A Prospective Study on Incidence, Risk Factors and Long-Term Outcome of Osteonecrosis in 694 Patients with Pediatric Acute Lymphoblastic Leukemia,. Blood. 2011; 118 (21): 3578. DOI: https://doi.org/10.1182/blood.V118.21.3578.3578Mariël L. te Winkel, Rob Pieters, Wim C. J. Hop, Hester A. de Groot-Kruseman, Maarten H. Lequin, Inge M. van der Sluis, Jos P. M. Bökkerink, Jan A. Leeuw, Marrie C. A. Bruin, R. Maarten Egeler, Anjo J. P. Veerman, Marry M. van den Heuvel-Eibrink; A Prospective Study on Incidence, Risk Factors and Long-Term Outcome of Osteonecrosis in 694 Patients with Pediatric Acute Lymphoblastic Leukemia,. Blood. 2011; 118 (21): 3578. DOI: https://doi.org/10.1182/blood.V118.21.3578.3578Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol. 2000 Sep 15; 18 (18): 3262–72. DOI: 10.1200/JCO.2000.18.18.3262Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol. 2000 Sep 15; 18 (18): 3262–72. DOI: 10.1200/JCO.2000.18.18.3262Власова О. А., Жидкова Е. М., Лылова Е. С., Демко А. Н., Якубовская М. Г., Валиев Т. Т., Лесовая Е. А. Селективные агонисты глюкокортикоидного рецептора как альтернатива глюкокортикоидам в терапии острого лимфобластного лейкоза: клинический ответ на глюкокортикоиды в сопоставлении c молекулярными эффектами in vitro. Онкогематология. 2025; 20 (2): 80–6.Vlasova O. A., Zhidkova E. M., Lylova E. S. et al. Selective glucocorticoid receptor agonists as an alternative to glucocorticoids in the treatment of acute lymphoblastic leukemia: clinical response to glucocorticoids compared with molecular effects in vitro. Onikogematologiya – Oncohematology 2025; 20 (2): 80–6. (In Russ.). DOI: https://doi.org/10.17650/1818‑8346‑2025‑20‑2‑80‑86Vlasova O. A., Zhidkova E. M., Lylova E. S. et al. Selective glucocorticoid receptor agonists as an alternative to glucocorticoids in the treatment of acute lymphoblastic leukemia: clinical response to glucocorticoids compared with molecular effects in vitro. Onikogematologiya – Oncohematology 2025; 20 (2): 80–6. (In Russ.). DOI: https://doi.org/10.17650/1818‑8346‑2025‑20‑2‑80‑86Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005 Jun; 129 (6): 734–45. DOI: 10.1111/j.1365–2141.2005.05509Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005 Jun; 129 (6): 734–45. DOI: 10.1111/j.1365–2141.2005.05509Georg Mann, Franco Locatelli, Giovanni Cazzaniga, Felix Niggli, Maurizio Aricò, Claus R. Bartram, Andishe Attarbaschi, Daniela Silvestri, Rita Beier, Giuseppe Basso, Richard Ratei, Andreas E. Kulozik, Luca Lo Nigro, Bernhard Kremens, Jeanette Greiner, Rosanna Parasole, Jochen Harbott, Roberta Caruso, Arend von Stackelberg, Elena Barisone, Claudia Rössig, Valentino Conter, Martin Schrappe. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127 (17): 2101–2112. DOI: https://doi.org/10.1182/blood‑2015‑09‑670729Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, Martin Stanulla, Andrea Biondi,Marina Kunstreich, Sebastian Kummer, Hans-Juergen Laws, Arndt Borkhardt, Michaela Kuhlen. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica 2016; 101 (11): 1295–1305. https://doi.org/10.3324/haematol.2016.147595Marina Kunstreich, Sebastian Kummer, Hans-Juergen Laws, Arndt Borkhardt, Michaela Kuhlen. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica 2016; 101 (11): 1295–1305. https://doi.org/10.3324/haematol.2016.147595te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica. 2008; 93 (10): 1570–1574.te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica. 2008; 93 (10): 1570–1574.Bernbeck B, Mauz-Korholz C, Zotz RB, Gobel U. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr. 2003; 215 (6): 327–331.Bernbeck B, Mauz-Korholz C, Zotz RB, Gobel U. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr. 2003; 215 (6): 327–331.Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11): 1096–1106.Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11): 1096–1106.Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol. 2001; 28 (12): 993–996.Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol. 2001; 28 (12): 993–996.Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin Proc. 2014; 89 (6): 817–834.Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin Proc. 2014; 89 (6): 817–834.Stuart FA, Segal TY, Keady S. Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child. 2005; 90 (5): 500–506.Stuart FA, Segal TY, Keady S. Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child. 2005; 90 (5): 500–506.Anastasopoulou S, Swann G, Andres-Jensen L, Attarbaschi A, Barzilai-Birenboim S, Erdelyi DJ, Escherich G, Hamadeh L, Harila A, Lopez-Lopez E, McGowan S, Möricke A, Putti C, Sagi JC, Schmiegelow K, Ullrich NJ, van der Sluis IM, Wahid QU, Winick N, Sramkova L, Zalcberg Y, Zapotocka E, Bhojwani D, Halsey C; Ponte Di Legno Neurotoxicity Working Group. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study. Br J Haematol. 2024 Oct; 205 (4): 1450–1459. DOI: 10.1111/bjh.19610Anastasopoulou S, Swann G, Andres-Jensen L, Attarbaschi A, Barzilai-Birenboim S, Erdelyi DJ, Escherich G, Hamadeh L, Harila A, Lopez-Lopez E, McGowan S, Möricke A, Putti C, Sagi JC, Schmiegelow K, Ullrich NJ, van der Sluis IM, Wahid QU, Winick N, Sramkova L, Zalcberg Y, Zapotocka E, Bhojwani D, Halsey C; Ponte Di Legno Neurotoxicity Working Group. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study. Br J Haematol. 2024 Oct; 205 (4): 1450–1459. DOI: 10.1111/bjh.19610Mrakotsky CM, Silverman LB, Dahlberg SE, Alyman MC, Sands SA, Queally JT, Miller TP, Cranston A, Neuberg DS, Sallan SE, Waber DP. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00–01. Pediatr Blood Cancer. 2011 Sep; 57 (3): 492–8. DOI: 10.1002/pbc.23060Mrakotsky CM, Silverman LB, Dahlberg SE, Alyman MC, Sands SA, Queally JT, Miller TP, Cranston A, Neuberg DS, Sallan SE, Waber DP. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00–01. Pediatr Blood Cancer. 2011 Sep; 57 (3): 492–8. DOI: 10.1002/pbc.23060Halberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR. Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys. 1992; 22: 13–16. DOI: 10.1016/0360–3016(92)90976-oHalberg FE, Kramer JH, Moore IM, Wara WM, Matthay KK, Ablin AR. Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys. 1992; 22: 13–16. DOI: 10.1016/0360–3016(92)90976-oMuriel AC, Burgers DE, Treyball AN, Vrooman LM, Adolf E, Samsel C. Risk factors for steroid-induced affective disorder in children with leukemia. Pediatr Blood Cancer. 2021; 68 (5): e28847Muriel AC, Burgers DE, Treyball AN, Vrooman LM, Adolf E, Samsel C. Risk factors for steroid-induced affective disorder in children with leukemia. Pediatr Blood Cancer. 2021; 68 (5): e28847Sklar CA, Mertens AC, Walter A. et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000; 35: 91–95. DOI: 10.1002/1096-911x(200008)35:2<91:: aid-mpo1>3.0.coSklar CA, Mertens AC, Walter A. et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol. 2000; 35: 91–95. DOI: 10.1002/1096-911x(200008)35:2<91:: aid-mpo1>3.0.coOeffinger KC, Mertens AC, Sklar CA, et al. Childhood Cancer Survivor Study. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003; 21: 1359–1365. DOI: 10.1200/JCO.2003.06.131Oeffinger KC, Mertens AC, Sklar CA, et al. Childhood Cancer Survivor Study. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003; 21: 1359–1365. DOI: 10.1200/JCO.2003.06.131Sklar CA, Robison LL, Nesbit ME, et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol. 1990; 8: 1981–1987. DOI: 10.1200/JCO.1990.8.12.1981Sklar CA, Robison LL, Nesbit ME, et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol. 1990; 8: 1981–1987. DOI: 10.1200/JCO.1990.8.12.1981Kravchenko N. E., Suetina O. A., Sachuk O. V., Valiev T. T. Mental health disorders in oncohematological diseases in children and adolescents. Medical Alphabet. 2023; (17): 26–31. (In Russ.).Кравченко Н. Е., Суетина О. А., Сачук О. В., Валиев Т. Т. Нарушения психического здоровья при онкогематологических заболеваниях у детей и подростков. Медицинский алфавит. 2023; 17: 26–31.Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol. 1993; 21: 333–339. DOI: 10.1002/mpo.2950210505Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol. 1993; 21: 333–339. DOI: 10.1002/mpo.2950210505Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK. Fertility issues for young adult survivors of childhood cancer. Psychooncology. 2004; 13: 689–690. DOI: 10.1002/pon.784Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK. Fertility issues for young adult survivors of childhood cancer. Psychooncology. 2004; 13: 689–690. DOI: 10.1002/pon.784Kanellopoulos A., Andersson S., Zeller B., Tamnes C. K., Fjell A. M., Walhovd K. B., Westlye L. T., Fosså S. D. Ruud E. Neurocognitive Outcome in Very Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia After Treatment with Chemotherapy Only. Pediatr Blood Cancer 2016; 63: 133–138. https://doi.org/10.1002/pbc.25690Kanellopoulos A., Andersson S., Zeller B., Tamnes C. K., Fjell A. M., Walhovd K. B., Westlye L. T., Fosså S. D. Ruud E. Neurocognitive Outcome in Very Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia After Treatment with Chemotherapy Only. Pediatr Blood Cancer 2016; 63: 133–138. https://doi.org/10.1002/pbc.25690Klyut A. S., Kharbediya V. Kh., Abrahamyan D. G. et al. Analysis of functional disorders in oncohematological diseases survivours. MD-Onco 2024; 4 (4): 129–35. (In Russ.). DOI: https:// doi.org/10.17650/2782‑3202‑2024‑4‑4‑129‑135Клют А. С., Харбедия В. Х., Абрамян Д. Г., Перятинский А. В., Глазырина А. А., Петряйкина Е. Е. Анализ функциональных нарушений у детей, излеченных от онкогематологических заболеваний. MD-Onco. 2024; 4 (4): 129–135.Pavlova M. G., Tselovalnikova T. Yu., Yudina A. E., Golounina O. O., Zilov A. V., Mazerkina N. A., Zheludkova O. G., Fadeev V. V. Growth hormone deficiency in childhood brain tumors and acute lymphoblastic leukemia survivors. Obesity and metabolism. 2021; 18 (4): 484–495. (In Russ.). DOI: https://doi.org/10.14341/omet12786Павлова М. Г., Целовальникова Т. Ю., Юдина А. Е., Голоунина О. О., Зилов А. В., Мазеркина Н. А., Желудкова О. Г., Фадеев В. В. Дефицит гормона роста у лиц, перенесших химиолучевую терапию злокачественных опухолей головного мозга и острого лимфобластного лейкоза в детстве. Ожирение и метаболизм. 2021; 18(4):484–495.Павлова М. Г., Целовальникова Т. Ю., Юдина А. Е., Голоунина О. О., Зилов А. В., Мазеркина Н. А., Желудкова О. Г., Фадеев В. В. Дефицит гормона роста у лиц, перенесших химиолучевую терапию злокачественных опухолей головного мозга и острого лимфобластного лейкоза в детстве. Ожирение и метаболизм. 2021; 18(4):484–495.

The authors declare that there are no conflicts of interest present.